Connect Biopharma Reports Topline Preliminary Results For Phase 1 Clinical Pharmacology Study Evaluating IV Rademikibart, Next-Gen, Anti-IL-4Rα Antibody

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced positive topline preliminary results from its Phase 1 clinical pharmacology study of IV rademikibart, an anti-IL-4Rα antibody. The study showed rapid improvement in FEV1 in asthma and COPD patients, with many experiencing increases of ≥200 mL within 15 minutes post-dosing, and mean improvements of ~200 - 400 mL maintained through Day 29. Recruitment is ongoing for Phase 2 Seabreeze STAT studies, with topline data expected in mid-2026.